Keystone Biologicals acquired by BioIVT in 2019
In August of 2019, BioIVT acquired Keystone Biologicals, Inc, a leading global provider of disease state plasma, serum and controls to the diagnostic and biotech industries. The acquisition expanded our portfolio of disease state biofluids, especially for the in vitro diagnostic (IVD) industry. By combining Keystone’s exceptional bulk disease state biofluids with our strength in procuring disease state tissue and clinical biofluids, BioIVT has expanded our leadership position for disease state biospecimens used in the development and manufacturing of IVD kits.
Read the full release for more details about the Keystone Biologicals acquisition